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Abstract
Objective—To describe epidemiology of bacterial meningitis in the World Health Organization 
Eastern Mediterranean Region countries and assist in introduction of new bacterial vaccines.
Study design—A laboratory-based sentinel surveillance was established in 2004, and up to 10 
countries joined the network until 2010. Personnel at participating hospitals and national public 
health laboratories received training in surveillance and laboratory methods and used standard 
clinical and laboratory-confirmed case definitions.
Results—Over 22 000 suspected cases of meningitis were reported among children ≤5 years old 
and >6600 among children >5 years old. In children ≤5 years old, 921 of 13 125 probable cases 
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(7.0%) were culture-confirmed. The most commonly isolated pathogens were S pneumoniae (27% 
of confirmed cases), N meningitidis (22%), and H influenzae (10%). Among culture-confirmed 
case-patients with known outcome, case-fatality rate was 7.0% and 12.2% among children ≤5 
years old and those >5 years old, respectively. Declining numbers of Haemophilus influenzae type 
b meningitis cases within 2 years post-Haemophilus influenzae type b conjugate vaccine 
introduction were observed in Pakistan.
Conclusions—Bacterial meningitis continues to cause significant morbidity and mortality in the 
Eastern Mediterranean Region. Surveillance networks for bacterial meningitis ensure that all sites 
are using standardized methodologies. Surveillance data are useful to monitor impact of various 
interventions including vaccines, but maintaining data quality requires consistent reporting and 
regular technical support.
Bacterial meningitis, which is associated with high morbidity and mortality, continues to be 
an important public health priority in the Eastern Mediterranean Region (EMR). Among 
children beyond the neonatal period, the majority of bacterial meningitis is caused by 
Haemophilus influenzae type b (Hib), Streptococcus pneumoniae (Sp), and Neisseria 
meningitidis (Nm), for which effective vaccines are currently available. In addition, the 
EMR has experienced multiple outbreaks of meningococcal meningitis over the last 3 
decades, especially in Saudi Arabia, where the Hajj takes place,1 and in Sudan,2 which is 
part of the “meningococcal meningitis belt”. Adequate laboratory-based surveillance is 
critical to generate data on disease burden, monitor the impact of vaccines postintroduction, 
and detect outbreaks early.
Pathogen-specific burden of disease data for bacterial meningitis are still limited in the 
EMR.3 Over the last decade, many countries in the region introduced Hib conjugate vaccines 
into routine childhood vaccination schedules which has led to a significant decrease in 
burden of disease.4 However, only a few countries in the region have introduced 
pneumococcal conjugate vaccines to date. The support from the GAVI Alliance has made it 
possible for low-income countries to introduce Hib and pneumococcal conjugate vaccines; 
however, most countries in the region, in particular low-middle income countries, have been 
struggling to introduce these vaccines, and meningococcal vaccine has just been introduced 
by the first country (Sudan) in the region. In addition to the financial constraints, the lack of 
adequate data on disease burden and the distribution of the various etiologies as well as 
serotypes/serogroups are often cited as important reasons for the delay in making evidence-
based decisions for vaccine introduction. Obtaining adequate data on meningitis burden 
requires a strong surveillance system and microbiology laboratory infrastructure, but it can 
also be affected by the high proportion of children who receive antibiotics before cultures 
are collected. Standardized procedures for surveillance and adequately trained laboratories 
can lead to a significant improvement in the quality of the data collected, however. The 
recent introduction of polymerase chain reaction has also helped increase the yield of tests 
from cerebrospinal fluid (CSF) specimens.
In January 2004, World Health Organization (WHO)/Eastern Mediterranean Regional Office 
(EMRO) sponsored a workshop to develop guidelines for establishing laboratory-based 
bacterial meningitis surveillance (BMS) in the region. This workshop resulted in 8 countries 
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becoming part of the network and developing their individual work plans. Countries started 
conducting surveillance in 2005–2006. The principal objectives of the surveillance are to 
monitor disease trends and detect outbreaks, provide data necessary for evidence-based 
decision making regarding vaccine introduction, monitor impact of vaccines and other 
interventions, and build national laboratory capacity.
In this article, we describe the results of the first few years of enhanced laboratory-based 
surveillance for bacterial meningitis, as well as the challenges associated with managing 
such a network.
Methods
The BMS network in the EMR is supported by the WHO/EMRO and partners. Launched in 
early 2004, the 10 EMR countries currently participating in the network include 
Afghanistan, Iran, Iraq, Egypt, Libya, Morocco, Pakistan, Sudan, Syria, and Yemen. Table I 
lists the participating hospitals and years for which data are provided for this analysis. 
Selection of hospitals participating in the enhanced BMS network was based on existing 
epidemiologic and laboratory capacity of each site along with the representativeness of the 
proposed surveillance population. Table II lists the years of introduction of the pediatric Hib 
and pneumococcal conjugate vaccines by EMR countries. One country (Syria) introduced 
Hib conjugate vaccine before surveillance was initiated, and 6 introduced Hib conjugate 
vaccine following surveillance initiation. Morocco was the first country to introduce 
pneumococcal conjugate vaccine (2010).
Participating hospitals apply consistent case definitions and standard operating procedures 
for all related clinical, epidemiologic, and laboratory procedures (http://www.who.int/nuvi/
surveillance/resources/en/index.html). Data collected using standardized case report forms 
are transmitted monthly to EMR regional coordinator for aggregation and analysis. 
Institutional review board review of BMS network was not needed as this was considered an 
ongoing national surveillance activity; all procedures were part of standard case 
management.
Case Definitions
The BMS network enrolled all persons older than 30 days; the neonatal period was excluded 
from surveillance because of the differing epidemiology and microbiology of bacterial 
meningitis in this age group. Case definitions used (suspected, probable, and confirmed 
bacterial meningitis) are described in Figure 1.
Specimen Collection and Laboratory Testing
Once a case of suspected meningitis was identified, CSF was collected and tested for 
glucose, protein, cell counts, gram stain, and culture. Where possible, CSF was also tested 
for presence of Sp, Hib, or Nm by latex agglutination. Standard testing methodologies used 
are described elsewhere.5
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Data Collection, Aggregation, and Analyses
Using a standardized case report form, information collected included patient demographics, 
clinical presentation of disease, vaccination status, laboratory results, and clinical outcome. 
Country data are securely transmitted to the WHO/EMRO for aggregation and analysis each 
month. Summary data are fed back to contributing countries and WHO.
For this study, we analyzed aggregated multisite data by 2 age groups: (1) ≤5 years old; and 
(2) >5 years old. We compared the distribution of clinical symptoms and discharge 
diagnoses by the 3 case definitions and by age group. In calculations of case-fatality ratios, 
we excluded cases with unknown outcome.
To evaluate trends over time, we restricted our analyses to the countries that had 2 or more 
years of surveillance data collected both before and after introduction of Hib or 
pneumococcal vaccine: Pakistan (King Edward Medical University, National Institute of 
Children Health) and Sudan (Khartoum General and Pediatric Hospital, Omdurman General 
and Pediatric Hospital). However, Sudan had incomplete reporting in 2006 because of 
interruption of financial support, thus, leaving only Pakistan for the trend analysis. Trends of 
bacterial meningitis prior to and following Hib conjugate vaccine introduction in Morocco 
have been presented previously.6
Results
Descriptive Epidemiology of Meningitis
Among the 10 participating EMR countries, 48 sentinel hospitals contributed surveillance 
data covering a reporting range of 4 months to 7 years (Table I). In total, almost 30 000 
cases were enrolled, of which 22 345 (77%) were in children aged 1 month-5 years old. The 
distribution of suspected, probable, and culture-confirmed cases among children ≤5 years 
old is presented in Figure 2. Of the 22 345 cases of children ≤5 years old who were 
suspected to have meningitis, 75% met the strict suspected case definition. The remaining 
25% were clinically suspected to have meningitis and enrolled into surveillance without 
meeting the criteria for a suspected case, mainly because fever was not present or 
information on fever was unavailable.
Lumbar puncture was performed in 20 850 (94%) cases of children ≤5 years old, of whom 
13 125 (63%) met the definition for probable meningitis. Culture confirmation of 1 of the 3 
vaccine-preventable bacteria was obtained for 653 (5%) of the probable cases in this age 
group.
Epidemiology of Meningitis by Bacterial Etiology
The distribution of confirmed bacterial pathogens isolated from CSF by the 2 age groups is 
shown in Table III (including all cases undergoing lumbar puncture regardless of whether or 
not they met the suspected or probable case definition). The most common pathogen 
identified in children ≤5 years old was Sp (27%) followed by Nm (22%) and Hib (10%). In 
children >5 years old, the most common pathogen identified was Nm (50%). As a single 
country, Sudan contributed the largest number of Nm cases (n = 130). In 2 BMS network 
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countries (Morocco, Syria), Hib conjugate vaccine was introduced prior to surveillance 
initiation; in 4 additional countries (Pakistan, Yemen, Libya, Iraq), Hib conjugate vaccine 
introduction occurred during the reported surveillance period. In Pakistan, the only country 
with uninterrupted data available before and after Hib conjugate vaccine introduction in 
2008, the percent of Haemophilus influenzae among cases of confirmed meningitis reported 
in 2010 (4.0%) had declined by 72% compared with the average for the 3 years prior to 
vaccine introduction (2005–2007; 14.2%). In comparison, the percent of Sp among 
confirmed cases of meningitis declined by 17% (45.8% [average, 2005–2007] vs 38.0%) 
(Table IV).
Among the 1263 culture-positive cases for which outcome information was available, 7.0% 
and 12.2% of children ≤5 years old and those >5 years old, respectively, died. The case 
fatality ratio was generally higher in the older age group (Table V). The distribution of 
clinical symptoms and discharge diagnoses—including case fatality ratios—for suspected, 
probable, and confirmed cases are shown in Tables VI and VII. In general, older cases (>5 
years old) were more likely to present with headache, neck rigidity, and vomiting and less 
likely with seizures and convulsions than young children. Fifty percent to 75% of survivors 
(all ages) were reported as having neurologic complications.
Discussion
This article describes the results of the first 6 years of surveillance for bacterial meningitis in 
a network of selected countries in the WHO EMR, first established in 2004. With thousands 
of cases of bacterial meningitis identified, this article highlights the burden of bacterial 
meningitis in the region, indicating its continuing public health importance. Though the 
network required significant efforts to be built, it enabled countries in the region to develop 
adequate bacteriologic laboratory capacity and to conduct surveillance using standard 
methods and procedures, thus, improving the quality of the data. This report also 
demonstrates how surveillance data can be useful to monitor the impact of public health 
interventions, such as the recent introduction of Hib conjugate vaccines, and also can help 
with policy decisions regarding the introduction of other new vaccines such as 
pneumococcal vaccines.
Morbidity and Mortality
Sp is the most important cause of bacterial meningitis currently among children ≤5 years old 
in the region, an expected finding given that most countries in the EMR have introduced Hib 
conjugate vaccines. These data support the fact that conjugate pneumococcal vaccines may 
further reduce morbidity and mortality from bacterial meningitis, in addition to its known 
impact on severe pneumonia.7,8 During this surveillance period, only a small proportion of 
available Sp isolates was serotyped. However, other reports have recently shown that either 
the 10-valent or 13-valent pneumococcal conjugate vaccine would provide adequate 
protection for the EMR countries.9
Teleb et al. Page 5
J Pediatr. Author manuscript; available in PMC 2018 February 07.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Vaccine Impact
In addition to supporting decisions for various interventions such as new vaccine 
introduction, surveillance allows countries to monitor the impact of such interventions. 
However, for surveillance data to be used for this purpose, efforts should be made to ensure 
surveillance methods and population covered, as well as data reporting, remain constant over 
time. In the absence of these essential requirements, it is very difficult to interpret the data 
and be confident when using the data for trend analyses, as illustrated in the case of Sudan 
and Pakistan.
Challenges Establishing a Network for Bacterial Disease Surveillance
Establishing bacterial surveillance for meningitis is challenging and requires significant 
support and capacity building both at the laboratory and the clinical levels. These challenges 
include providing adequate training initially and through regular follow-up, ensuring a 
continuity in specimen processing even when the laboratory is not open at all times, and 
maintaining adequate laboratory supplies and management. For example, as seen in this 
article, we found that many confirmed cases did not meet the “suspected” case definition, 
indicating that clinicians were still using their clinical judgment to enroll meningitis cases. 
However, when these patients underwent lumbar puncture, a large proportion of them met 
the probable case definition, and the rate of culture confirmation was similar to those who 
met the suspected case definition (Figure 2). If we had excluded these cases early on, we 
would have missed a significant proportion of disease. In addition, the suspected case 
definition might not have been consistently implemented, resulting in inaccurate or 
incomplete collection of information on the presenting signs and symptoms. It is also 
possible that use of antibiotics and antipyretics prior to admission and evaluation at the 
hospital may have both changed the clinical presentation—as indicated by signs and 
symptoms collected on the case report form—of some patients who are still suspected of 
having possible meningitis by the physicians evaluating them, and also resulted in lower 
rates of culture-confirmed infections.
In addition, the variability of performance between countries and between hospitals within 
the same country, personnel turnover and the requirement of regular training, and the need 
for continuous monitoring added to the difficulties encountered. Challenges in coordinating 
a surveillance network for Hib and pneumococcal disease had been discussed earlier.10 Also, 
the network sought to establish meningitis surveillance in countries with inadequate 
surveillance infrastructure. WHO worked closely with the ministries of health and other 
partners in the various countries to strengthen the national public health laboratories and 
enable them to play a leadership role in supporting the sentinel surveillance sites. In addition 
to the expected challenges, this region has experienced multiple political conflicts, often 
resulting in difficulties in visiting some of the sites, as well as shipping materials and 
specimens across borders.
Despite the variety of challenges encountered, the benefits of this regional meningitis 
surveillance network are multifold. Member countries have already used the data for public 
health decision making such as introduction of Hib conjugate vaccine in Iraq and 
development of applications for Global Alliance for Vaccines and Immunization support of 
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pneumococcal vaccine introduction in Afghanistan, Yemen, and Sudan. In some major 
hospitals, bacterial diseases surveillance was established for the first time. Development of 
capacity for laboratory surveillance of bacterial diseases in public hospitals has benefited 
other programs, which use the same microbiologic platform to identify other causes of 
meningitis such as typhoid and salmonella, in addition to improving laboratory practices 
overall such as reducing contamination rates.
Starting in 2010, the EMR joined the WHO Invasive Bacterial Diseases Surveillance 
network to become part of a global network that can benefit from additional technical 
support. Many lessons can be learned from this surveillance network that will be useful for 
the next phase in the region. These include the benefits of capacity building, value of site 
visits, the importance of consistent reporting using standardized case definitions and 
operating procedures, and the need for regional meetings to encourage collaboration and to 
motivate poorly performing surveillance sites. As countries gain more experience, and as the 
political situation in the EMR continues to evolve, decisions need to be made at the regional 
and country level about the optimal surveillance model, depending on how countries plan to 
use the data to support public health decisions regarding various interventions, such as the 
introduction of life saving conjugate pneumococcal vaccines.
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BMS Bacterial meningitis surveillance
CSF Cerebrospinal fluid
EMR Eastern Mediterranean Region
EMRO Eastern Mediterranean Regional Office
Hib Haemophilus influenzae type b
Nm Neisseria meningitidis
Sp Streptococcus pneumoniae
WHO World Health Organization
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Figure 1. 
Case definitions for acute BMS. PCR, polymerase chain reaction.
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Figure 2. 
Distribution of suspected, probable, and culture-confirmed cases among children <5 years 
old. *Cases were classified as not meeting suspected case definition due to missing clinical 
data. †Culture-confirmed: Any case with positive culture of CSF with identification of 
Haemophilus influenzae, Sp, Nm (gold standard for confirmed cases). Total confirmed 
includes other bacteria or nonspecified bacteria. Note: PCR and antigen detection data not 
included. LP, lumbar puncture
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Table I
Participating countries, sentinel hospitals, and years* of data collection and contribution
Country Sentinel hospitals
Years of data
contributed
Afghanistan Indera Gandi Hospital 2008–2010
Egypt Abbassia Fever Hospital 2009–2010
Alexandria Fever Hospital
Imbaba Fever Hospital
Mahala Fever Hospital
Qena Fever Hospital
Iran Abouza Khouzestan 2007–2008
Besat Kordestan
Bou Ali Sina Mazandaran
Iraq Al-Kadhymia 2007–2010
Central Child
Children Welfare
Tikrit
Babil Pediatric Hospital
Basrah General Hospital
Elwiyah Pediatric Hospital
Libya Benghazi Pediatric Hospital 2006–2008
Batnan Medical Center
Zliten General Hospital
Tripoli Pediatric Hospital
Morocco Ibn Ruchd University Hospital, Casablanca National meningitis surveillance since 2004; enrollment in network 
in 2007
Rabat Pediatric University Hospital
Beni Malal General Hospital, Beni Mallal
Mohamed Elkhamis General Hospital, Tanger
Pakistan National Institute of Child Health, Karachi 2005–2010
Mayo hospital, King Edward Medical University, Lahore
Childrens Hospital
Sudan Umdorman Pediatric Hospital 2004–2010
ElObayed Hospital
Khartoum Pediatric Hospital
Madani Pediatric Hospital
Dongola Hospital
Gadaref Hospital
Niyala Hospital
Port Sudan Hospital
Syria Al Asad Hospital, Hama 2005–2010
Al Basel Hospital, Tartous
Pediatric Hospital, Aleppo
Al Mogtahed Hospital, Damascus
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Teleb et al. Page 12
Country Sentinel hospitals
Years of data
contributed
National Hospital, Lattakia
Al Asad Hospital, Lattakia
Pediatric Hospital, Damascus
Yemen El Saudi Hospital, Hajjeh 2004–2010
El Swedy Hospital, Taiz
El Wehda Hospital, Aden
El Sabe’en Hospital, Sana’a
El Thawra, Sana’a
El Thawra, Ebb
*
For each country, not all hospitals contributed data for all years.
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Teleb et al. Page 13
Table II
Introduction of the pediatric Hib and pneumococcal conjugate vaccines by EMR countries
Country Year of Hib introduction Year of PCV introduction
Afghanistan January 2009 Conditional GAVI approval for introduction
Iran No current plans for introduction No current plans for introduction
Iraq January 2012 No current plans for introduction
Libya 2007 No current plans for introduction
Morocco 2007 October 2010
Pakistan October 2008–January 2009 Phased introduction began October 2012
Sudan January 2008 Introduction planned for 2013
Syria 2001 No current plans for introduction
Yemen 2005 January 2011
PCV, pneumococcal conjugate vaccine; GAVI, Global Alliance for Vaccines and Immunization.
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Table VI
Frequency* of clinical symptoms, prior use of antibiotics, and disease sequelae for suspected, probable, and 
confirmed cases ≤5 years old
Case definition
Suspected
N = 16 811
Probable†
N = 13 125
Confirmed cases meeting
probable case definition
N = 921
Confirmed cases that did not
meet probable case definition
N = 104
Clinical presentations: signs and symptoms
  Fever 86% 89% 90% 83%
  Headache 11% 12% 17% 9%
  Neck rigidity 23% 26% 36% 13%
  Vomiting 41% 40% 51% 39%
  Skin rash 3% 3% 4% 4%
  Petechiae 2% 2% 5% 3%
  Seizures/convulsions 68% 69% 59% 65%
  Altered consciousness 26% 26% 31% 28%
  Bulging fontanelle 14% 15% 23% 14%
  Coma 8% 7% 8% 6%
Antibiotics received prior to lumbar puncture 30% 24% 27% 43%
Disease sequelae
  Outcome (death) 3% 3% 9% 3%
  Neurologic complications (any) 75% 75% 54% 77%
*
Proportion of cases with a given symptom. Cases with missing responses are excluded.
†
Includes cases that did not meet probable case definition because fever was absent at presentation or the presence of fever was unknown.
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Table VII
Frequency* of clinical symptoms, prior use of antibiotics, and disease sequelae for suspected, probable, and 
confirmed cases >5 years of age
Case definition
Suspected
N = 5331
Probable†
N = 4898
Confirmed cases meeting
probable case definition
n = 398
Confirmed cases that did not
meet probable case definition
n = 20
Clinical presentations: signs and symptoms
  Fever 82% 85% 87% 80%
  Headache 70% 72% 73% 56%
  Neck rigidity 64% 68% 82% 58%
  Vomiting 67% 69% 70% 60%
  Skin rash 5% 4% 7% 13%
  Petechiae 5% 5% 9% 0
  Seizures/convulsions 38% 36% 39% 54%
  Altered consciousness 33% 33% 46% 17%
  Coma 14% 13% 24% 8%
Antibiotics received prior to lumbar puncture 31% 29% 25% 36%
Disease sequelae
  Outcome (death) 6% 7% 19% 5%
  Neurological complications (any) 70% 69% 50% 74%
*
Proportion of cases with a given symptom. Cases with missing responses were excluded.
†
Includes cases that did not meet probable case definition because fever was absent at presentation or the presence of fever was unknown.
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